Potential to enhance the prescribing of generic drugs in patients with mental health problems in Austria; implications for the future

Brian Godman, Anna Bucsics, Thomas Burkhardt, Jutta Piessnegger, Manuela Schmitzer, Corrado Barbui, Emanuel Raschi, Marion Bennie, Lars L Gustafsson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Scrutiny over
pharmaceutical expenditure is increasing leading to multiple reforms. This
includes Austria with measures to lower generic prices and enhance their
utilization. However the situation for newer antidepressants and atypical
antipsychotic medicines (AAPs) is different to PPIs, statins, and
renin-angiotensin inhibitor drugs with greater tailoring of therapy and no wish
to switch products in stable patients. Authorities welcome generics though
given the high costs particularly of single-sourced AAPs. Assess (a)
changes in utilization of venlafaxine versus other newer antidepressants before
and after availability of generics, (b) utilization of generic versus
originator venlafaxine, (c) price reductions of venlafaxine over time and their
influence on total expenditure, (d) utilization of risperidone versus other
AAPs, (e) suggest potential additional reforms that could be introduced if
pertinent to further enhance the use of generics. 
A quasi-experimental study design with a segmented time series and an
observational study. Utilization measured in defined daily doses (DDDs) and
total expenditure per DDD and over time. No appreciable changes in the
utilization of venlafaxine and risperidone after generics. The reduction in
expenditure/DDD for venlafaxine decreased overall expenditure on newer
antidepressants by 5% by the end of the study versus just before generics
despite a 37% increase in utilization. Expenditure will further decrease if
reduced prescribing of duloxetine. Depression, schizophrenia, and bipolar
diseases are complex diseases. As a result, specific measures are needed to
encourage the prescribing of generic risperidone and venlafaxine when multiple
choices are appropriate. Authorities cannot rely on a "Hawthorne"
effect between classes to enhance the use of generics. Measures may include
prescribing restrictions for duloxetine. No specific measures planned for AAPs
with more multiple-sourced AAPs becoming available

LanguageEnglish
Article number198
Number of pages10
JournalFrontiers in Pharmacology
Volume3
Early online date7 Jan 2013
DOIs
Publication statusPublished - 2013

Fingerprint

Generic Drugs
Austria
Health Expenditures
Mental Health
Antidepressive Agents
Risperidone
Epidemiologic Effect Modifiers
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensins
Venlafaxine Hydrochloride
Schizophrenia
Research Design
Depression
Costs and Cost Analysis
Pharmaceutical Preparations

Keywords

  • prescribing
  • generic drugs
  • patients
  • mental health
  • austria
  • implications
  • pharmaceutical expenditure
  • healthcare reform
  • atypical antipsychotic medicines
  • AAPs
  • renin-angiotensin inhibitor drugs
  • PPIs
  • statins
  • antidepressants
  • drug utilization studies
  • generics
  • risperidone
  • schizophrenia

Cite this

Godman, Brian ; Bucsics, Anna ; Burkhardt, Thomas ; Piessnegger, Jutta ; Schmitzer, Manuela ; Barbui, Corrado ; Raschi, Emanuel ; Bennie, Marion ; Gustafsson, Lars L. / Potential to enhance the prescribing of generic drugs in patients with mental health problems in Austria; implications for the future. In: Frontiers in Pharmacology . 2013 ; Vol. 3.
@article{d65ebbfddf9d4fa98e518b4859a46428,
title = "Potential to enhance the prescribing of generic drugs in patients with mental health problems in Austria; implications for the future",
abstract = "Scrutiny over pharmaceutical expenditure is increasing leading to multiple reforms. This includes Austria with measures to lower generic prices and enhance their utilization. However the situation for newer antidepressants and atypical antipsychotic medicines (AAPs) is different to PPIs, statins, and renin-angiotensin inhibitor drugs with greater tailoring of therapy and no wish to switch products in stable patients. Authorities welcome generics though given the high costs particularly of single-sourced AAPs. Assess (a) changes in utilization of venlafaxine versus other newer antidepressants before and after availability of generics, (b) utilization of generic versus originator venlafaxine, (c) price reductions of venlafaxine over time and their influence on total expenditure, (d) utilization of risperidone versus other AAPs, (e) suggest potential additional reforms that could be introduced if pertinent to further enhance the use of generics.  A quasi-experimental study design with a segmented time series and an observational study. Utilization measured in defined daily doses (DDDs) and total expenditure per DDD and over time. No appreciable changes in the utilization of venlafaxine and risperidone after generics. The reduction in expenditure/DDD for venlafaxine decreased overall expenditure on newer antidepressants by 5{\%} by the end of the study versus just before generics despite a 37{\%} increase in utilization. Expenditure will further decrease if reduced prescribing of duloxetine. Depression, schizophrenia, and bipolar diseases are complex diseases. As a result, specific measures are needed to encourage the prescribing of generic risperidone and venlafaxine when multiple choices are appropriate. Authorities cannot rely on a {"}Hawthorne{"} effect between classes to enhance the use of generics. Measures may include prescribing restrictions for duloxetine. No specific measures planned for AAPs with more multiple-sourced AAPs becoming available",
keywords = "prescribing, generic drugs, patients, mental health, austria, implications, pharmaceutical expenditure, healthcare reform, atypical antipsychotic medicines , AAPs, renin-angiotensin inhibitor drugs, PPIs, statins, antidepressants, drug utilization studies, generics, risperidone, schizophrenia",
author = "Brian Godman and Anna Bucsics and Thomas Burkhardt and Jutta Piessnegger and Manuela Schmitzer and Corrado Barbui and Emanuel Raschi and Marion Bennie and Gustafsson, {Lars L}",
year = "2013",
doi = "10.3389/fphar.2012.00198",
language = "English",
volume = "3",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",

}

Potential to enhance the prescribing of generic drugs in patients with mental health problems in Austria; implications for the future. / Godman, Brian; Bucsics, Anna; Burkhardt, Thomas; Piessnegger, Jutta; Schmitzer, Manuela; Barbui, Corrado; Raschi, Emanuel; Bennie, Marion; Gustafsson, Lars L.

In: Frontiers in Pharmacology , Vol. 3, 198, 2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potential to enhance the prescribing of generic drugs in patients with mental health problems in Austria; implications for the future

AU - Godman, Brian

AU - Bucsics, Anna

AU - Burkhardt, Thomas

AU - Piessnegger, Jutta

AU - Schmitzer, Manuela

AU - Barbui, Corrado

AU - Raschi, Emanuel

AU - Bennie, Marion

AU - Gustafsson, Lars L

PY - 2013

Y1 - 2013

N2 - Scrutiny over pharmaceutical expenditure is increasing leading to multiple reforms. This includes Austria with measures to lower generic prices and enhance their utilization. However the situation for newer antidepressants and atypical antipsychotic medicines (AAPs) is different to PPIs, statins, and renin-angiotensin inhibitor drugs with greater tailoring of therapy and no wish to switch products in stable patients. Authorities welcome generics though given the high costs particularly of single-sourced AAPs. Assess (a) changes in utilization of venlafaxine versus other newer antidepressants before and after availability of generics, (b) utilization of generic versus originator venlafaxine, (c) price reductions of venlafaxine over time and their influence on total expenditure, (d) utilization of risperidone versus other AAPs, (e) suggest potential additional reforms that could be introduced if pertinent to further enhance the use of generics.  A quasi-experimental study design with a segmented time series and an observational study. Utilization measured in defined daily doses (DDDs) and total expenditure per DDD and over time. No appreciable changes in the utilization of venlafaxine and risperidone after generics. The reduction in expenditure/DDD for venlafaxine decreased overall expenditure on newer antidepressants by 5% by the end of the study versus just before generics despite a 37% increase in utilization. Expenditure will further decrease if reduced prescribing of duloxetine. Depression, schizophrenia, and bipolar diseases are complex diseases. As a result, specific measures are needed to encourage the prescribing of generic risperidone and venlafaxine when multiple choices are appropriate. Authorities cannot rely on a "Hawthorne" effect between classes to enhance the use of generics. Measures may include prescribing restrictions for duloxetine. No specific measures planned for AAPs with more multiple-sourced AAPs becoming available

AB - Scrutiny over pharmaceutical expenditure is increasing leading to multiple reforms. This includes Austria with measures to lower generic prices and enhance their utilization. However the situation for newer antidepressants and atypical antipsychotic medicines (AAPs) is different to PPIs, statins, and renin-angiotensin inhibitor drugs with greater tailoring of therapy and no wish to switch products in stable patients. Authorities welcome generics though given the high costs particularly of single-sourced AAPs. Assess (a) changes in utilization of venlafaxine versus other newer antidepressants before and after availability of generics, (b) utilization of generic versus originator venlafaxine, (c) price reductions of venlafaxine over time and their influence on total expenditure, (d) utilization of risperidone versus other AAPs, (e) suggest potential additional reforms that could be introduced if pertinent to further enhance the use of generics.  A quasi-experimental study design with a segmented time series and an observational study. Utilization measured in defined daily doses (DDDs) and total expenditure per DDD and over time. No appreciable changes in the utilization of venlafaxine and risperidone after generics. The reduction in expenditure/DDD for venlafaxine decreased overall expenditure on newer antidepressants by 5% by the end of the study versus just before generics despite a 37% increase in utilization. Expenditure will further decrease if reduced prescribing of duloxetine. Depression, schizophrenia, and bipolar diseases are complex diseases. As a result, specific measures are needed to encourage the prescribing of generic risperidone and venlafaxine when multiple choices are appropriate. Authorities cannot rely on a "Hawthorne" effect between classes to enhance the use of generics. Measures may include prescribing restrictions for duloxetine. No specific measures planned for AAPs with more multiple-sourced AAPs becoming available

KW - prescribing

KW - generic drugs

KW - patients

KW - mental health

KW - austria

KW - implications

KW - pharmaceutical expenditure

KW - healthcare reform

KW - atypical antipsychotic medicines

KW - AAPs

KW - renin-angiotensin inhibitor drugs

KW - PPIs

KW - statins

KW - antidepressants

KW - drug utilization studies

KW - generics

KW - risperidone

KW - schizophrenia

U2 - 10.3389/fphar.2012.00198

DO - 10.3389/fphar.2012.00198

M3 - Article

VL - 3

JO - Frontiers in Pharmacology

T2 - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 198

ER -